Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis

Core Insights - Reviva Pharmaceuticals has received a European patent for brilaroxazine, which is aimed at treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) [1][2] - The patent strengthens the company's intellectual property portfolio and highlights the therapeutic potential of brilaroxazine in chronic fibrotic disorders [2] - Brilaroxazine has shown a novel mechanism of action targeting serotonin signaling, which is involved in the pathogenesis of pulmonary fibrosis [1][3] Company Overview - Reviva Pharmaceuticals is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [6] - The company's pipeline includes two drug candidates, brilaroxazine and RP1208, both of which are new chemical entities discovered in-house [6] Clinical Development - Brilaroxazine has demonstrated positive topline data from the global Phase 3 RECOVER trial in schizophrenia, meeting all primary and secondary endpoints with significant reductions in symptoms [4] - The drug has a well-tolerated side effect profile and lower discontinuation rates compared to placebo [4] - Reviva plans to expand the clinical development of brilaroxazine into other neuropsychiatric indications, including bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) [4][5] Regulatory Status - Brilaroxazine has received Orphan Drug Designation from the FDA for the treatment of IPF and pulmonary arterial hypertension (PAH) [5] - The company believes it has completed a comprehensive set of regulatory compliant toxicology and safety pharmacology studies for brilaroxazine [4]